OnCo
ideasIdea

Plan the second CAR-T target before the first one is lost

Cell therapies fail when the tumour stops showing the marker they were built to find. Preparing an alternative product in advance would let doctors switch quickly.

Antigen-negative relapse accounts for a substantial share of CAR-T failures in B-cell malignancies and is emerging in multiple myeloma. Strategies include dual-target and tandem CARs, sequential products, and adaptor or universal CAR platforms whose specificity is set by a separately dosed molecule. A pragmatic programme would monitor antigen density after infusion and have the alternative product manufactured or an adaptor available before relapse.

Hypothesis
Pre-planned antigen switching, triggered by falling antigen density or early molecular relapse rather than by overt relapse, improves durable remission rates compared with reactive switching at relapse.
Rationale
Antigen loss is detectable before clinical relapse using flow cytometry and MRD assays; the delay in manufacturing a second product is usually what makes switching too late.
What would test it
Single-arm study of antigen-density and MRD-triggered pre-emptive switching in relapsed B-cell malignancy, with durable remission at two years compared with historical reactive management.
Maturity
early clinical
Who has to act
clinic
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks

Connected

13top

Pages like this

not linked directly; found by shared links

cancers

3
Acute lymphoblastic leukaemiaDiffuse large B-cell lymphomaMultiple myeloma

technologies

3
Allogeneic (off-the-shelf) cell therapyCAR-T cell therapyMRD / molecular residual disease testing

targets

4
BCMACD19CD20GPRC5D

terms

1
Minimal / molecular residual disease (MRD)

bottlenecks

2
Acquired resistance to every therapyManufacturing cost and time for living and radioactive medicines